Devyser strengthens U.S. market presence with CMS pricing for PrenatalDetect RHD test
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
With the IVDR transition approaching, European clinical laboratories are preparing for changes that...
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
RhD incompatibility remains a critical concern in prenatal care, with the potential to cause...
Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation...
Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of...
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for...